BHV 1300
Alternative Names: BHV-1300Latest Information Update: 16 Aug 2024
At a glance
- Originator Biohaven Pharmaceuticals
- Class Antirheumatics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
- Preclinical Immunological disorders
Most Recent Events
- 08 Aug 2024 Pharmacokinetics and adverse events data phase-I trial in Rheumatoid arthritis released by Biohaven Therapeutics
- 12 Jun 2024 Pharmacodynamics and pharmacokinetics data from preclinical studies in Immunological disorders presented at 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 29 May 2024 Updated adverse events and pharmacodynamics data from a phase I trial (In volunteers) released by Bioheaven